Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical-level guide to recognizing, preventing, and managing adverse events with SGLT2 inhibitors, covering DKA, UTIs, genital mycotic infections, volume depletion, and limb amputation risk, with inline citations to primary sources.
Read clinical reviewA complete MD/PharmD-level guide to SGLT2 inhibitor billing codes, prior-authorization requirements, step-therapy rules, and appeals strategy for empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
Read clinical reviewA clinical-grade monitoring bundle for SGLT2 inhibitors covering baseline workup, ongoing labs, safety signals, dose adjustments, and stopping rules, written at MD/PharmD level.
Read clinical reviewA prescriber-level summary of SGLT2 inhibitor use across special populations: heart failure, CKD, elderly patients, pregnancy, and more. Includes trial data, dosing guidance, and safety considerations.
Read clinical reviewA clinician-level guide to SGLT2 inhibitor initiation, dose titration, and safe tapering. Covers empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin with evidence from EMPA-REG OUTCOME, DAPA-HF, CREDENCE, and current ADA/ACC guidelines.
Read clinical reviewEvidence-based guide to choosing between empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin based on indication, trial data, renal function, and formulary access.
Read clinical review